标题：Age-Specific Seroprevalence of HIV, Hepatitis B Virus, and Hepatitis C Virus Infection Among Injection Drug Users Admitted to Drug Treatment in 6 US Cities
摘要：Objectives. This study measured age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus (HCV) infection among injection drug users (IDUs) admitted to drug treatment programs in 6 US cities. Methods. Remnant sera collected from persons entering treatment with a history of illicit drug injection were tested for antibodies to HIV, hepatitis C (anti-HCV), and hepatitis B core antigen (anti-HBc). Results. Prevalence of anti-HBc and anti-HCV increased with age and reached 80% to 100% among older IDUs in all 6 cities. Although overall age-specific HIV prevalence was lower than anti-HCV or anti-HBc, this prevalence was greater in the Northeast than in the Midwest and West. Conclusions. The need continues for effective primary prevention programs among IDUs specifically targeting young persons who have recently started to inject drugs. (Am J Public Health. 2002;92:385–387) Injection drug use has played an important role in parenteral transmission of HIV, hepatitis B virus (HBV), and hepatitis C virus (HCV). Several studies have described high prevalence of antibodies to HCV (anti-HCV) and hepatitis B core antigen (anti-HBc) among injection drug users (IDUs) in the United States and other countries 1– 3 and have measured coinfection rates of HIV, HBV, and HCV. 1, 2, 4– 6 Sera were originally collected from 1993 to 1994 for the Centers for Disease Control and Prevention (CDC) national HIV seroprevalence surveys to measure the prevalence of anti-HBc, anti-HCV, and HIV among IDUs entering treatment in 6 US cities: Newark, NJ; Baltimore, Md; Detroit, Mich; Denver, Colo; San Francisco, Calif; and Seattle, Wash. By using standardized methods 7, 8 for measuring prevalence in these 6 cities, we added age-specific and geographic data to the existing body of information about the national HBV, HCV, and HIV endemic among IDUs.
